• Glycoprotein VI (GPVI) binds collagen, starting thrombogenesis, and fibrin, stabilizing thrombi.
Introduction
Myocardial infarction and ischemic stroke, leading causes of disability and death worldwide [1] , usually result from atherosclerotic plaque rupture, leading to arterial thrombus formation followed by distal tissue infarction; platelets are crucial for the development of such thrombi. Disruption of the thrombo-protective endothelial layer within blood vessels during plaque rupture exposes collagen and tissue factor (TF). Platelet GPIb-IX-V binds to von Willebrand factor (VWF) deposited on exposed subendothelial collagens, slowing them down so Glycoprotein VI (GPVI) can bind to the collagen, which initiates a signaling cascade leading to thrombus formation [2, 3] . A dimer consisting of two GPVI-monomers is the functionally active form of this receptor, which is constitutively present (about 20% of the total GPVI) on resting platelets [4] . GPVI-dimers recognize Gly-Pro-Hyp (GPO) peptide repeats on collagen [5, 6] and once platelets adhere via GPVI, activation of integrin a2b1 supports firm adhesion to collagen [7] .
The subsequent growth and stability of a clot relies on coordinated activation of both the collagen pathway and TF (tissue factor) pathway [8] , which can also form thrombi independent of collagen exposure [9] , relying on thrombin (factor IIa) generation via the proteolytic extrinsic coagulation cascade. Thrombin generates insoluble fibrin from soluble circulating fibrinogen, which polymerizes and acts to stabilize the growing clot via platelet receptor integrin aIIbb3 [10, 11] .
Human fibrinogen molecules are comprised of six disulfide-linked polypeptide chains (Aa, Bb, c) 2 organized as outer D-domains containing the C-termini of the three chains, connected to a central E-domain. Thrombin cleaves fibrinopeptides A and B from the N-termini of the a-and b-chains within the E-domain, exposing new binding sites that allow fibrin polymerization through linking to one or two D-domains in an end-to-middle configuration [12] . Ddomain c-chains undergo reciprocal crosslinking mediated by FXIIIa, leading to a strengthened fibrin mesh [13] . The peptide Gly-Pro-Arg-Pro (GPRP), which binds to the fibrin polymerization sites in the D-domain, inhibits its binding to an adjacent E-domain, leading to formation of noncrosslinked, or monomeric fibrin [14] . Plasmin can act on fibrinogen to release D-or E-domains separately, or on polymerized fibrin to release D-dimer, typically consisting of two FXIIIa crosslinked D-domains from an original fibrinogen molecule [15] .
Initially, aIIbb3 is converted to its high-affinity form, enabling binding to fibrinogen and fibrin, leading to platelet aggregation, thrombus growth and formation of a hemostatic plug [16] . The complex role that aIIbb3 plays in thrombus formation has already been extensively investigated, but translation of its inhibition to an antiplatelet agent has not been successful in conditions such as ischemic stroke [17] .
It has been long suspected that GPVI plays a role in thrombus growth independent of collagen exposure through ligands such as thrombin [18, 19] , laminin [20] , fibronectin [21, 22] and vitronectin [23] . Recently, it has been reported that GPVI interacts with polymerized fibrin to facilitate thrombus growth [24] [25] [26] .
The present study provides evidence indicating that the collagen-binding, dimeric form of GPVI, is also able to recognize the D-domain, a region universal to fibrinogen, D-fragment (resulting from proteolytic cleavage of fibrinogen), D-dimer, and monomeric and polymerized fibrin. The binding site on GPVI-dimer for the D-domain is proximate to its collagen-binding site and GPVI-dimer assists aIIbb3 in thrombus growth and stabilization, suggesting that GPVI-dimer could be the central platelet receptor linking both collagen and TF pathways in thrombosis.
Materials and methods
Fibrinogen/fibrinogen derivatives Figure S1 summarizes the commercial preparations of human fibrinogen and derivatives used; SDS-PAGE confirmed the manufacturer's stated purity. Preliminary studies showed that all the listed fibrinogens gave similar results. We used Fibrinogen 3 (Fbg-3) in this study because it was plasminogen-, VWF-and fibronectindepleted, but not factor XIII-depleted.
Recombinant GPVI-dimer and -monomer GPVI ex is a recombinant protein comprising the extracellular domain of GPVI, including the collagen binding portions D1D2 and most of the highly glycosylated extracellular stem portion. GPVI-Fc 2 is a fusion protein of the GPVI extracellular domain (same amino acid sequence as GPVI ex ) and the Fc domain of IgG, which spontaneously dimerizes ([GPVI-Fc] 2 , abbreviated as GPVI-Fc 2 ). Both proteins were designed and characterized by M. Moroi and colleagues [4, 27] .
Collagen substrates (synthesized and crosslinked in-house) CRP-XL (crosslinked collagen-related peptide; GCO-(GPO) 10 -GCOG-NH 2 ) is a GPVI-specific agonist [28] and GPP10-XL is its inactive analogue (GCP-(GPP) 10 G-NH 2 ) [5] .
GPVI-dimer-specific antibodies mFab-F is a GPVI-dimer-specific inhibitory Fab [3] that recognizes the dimers on resting platelets. GPVI-dimerspecific non-inhibitory 204-11 Fab [4] recognizes the GPVI-dimers on resting and activated platelets. Both antibodies were developed by M Moroi and colleagues.
Immobilization of fibrinogen substrates and collagens
For ELISA, static adhesion, confocal microscopy and flow adhesion, respectively, 96-well black optical polymer-bottom ELISA plates (Nunc A/S, Roskilde, Denmark), Maxisorp ELISA plates (Nunc A/S), glass-bottomed dishes (10-mm, No. 0; MatTek, Ashland, MA, USA) or glass slides were incubated with fibrinogen or collagenous substrates in phosphate-buffered saline (PBS; for all substrates except Horm, which was diluted in supplied diluent), overnight at 4°C; details are provided in the figure legends. The immobilized surfaces were blocked by incubating with 1% bovine serum albumin (BSA)/PBS for 1 h, washed twice with PBS, and used for experiments.
Polymerized fibrin (pFibrin) was prepared by adding thrombin (2 U mL À1 ; Sigma-Aldrich, Dorset, England)
to Fbg-3 (10 lg mL À1 unless otherwise stated), and incubated for 30 min at RT, aliquoted to the surface to be coated and left overnight at 4°C. The coated surface was blocked with 1% BSA, treated with hirudin or protease inhibitor cocktail for 10 min to inhibit active thrombin, and washed with PBS. The presence of fibrin strands was confirmed by staining with antifibrin (UC45)/Alexa-Fluor-Plus 555 anti-mouse IgG (ThermoFisher Scientific, Warrington, UK); Fig. 4 (B) shows a representative image. Immobilized monomeric fibrin (mFibrin) was prepared by adding GPRP (2 mM) to Fbg-3 (10 lg mL
À1
, unless stated otherwise) and incubated for 30 min at RT before adding thrombin as above; other procedures are the same as for pFibrin.
ELISA analysis of GPVI-dimer and GPVI-monomer binding to fibrinogen and its derivatives GPVI binding to immobilized substrates was measured by ELISA as described previously [4] . Bound GPVI was measured by reacting the wells with 1G5 (mouse anti-pan GPVI Mab; Biocytex, Marseille, France) [20, 29] followed by IRDye Ò 800CW goat anti-mouse IgG (Licor Biosciences, Cambridge, UK) or Alexafluor 647-conjugated anti-human Fc (BioLegend, London, UK).
Washed platelets
ACD-anticoagulated blood from healthy volunteers or the Glanzmann thrombasthenic (GT) patient was obtained with informed consent, in accordance with the Treaty of Helsinki. Washed platelets were prepared as described previously [30] and resuspended in HEPES-Tyrode's buffer (HT: 134 mM NaCl, 0.34 mM Na 2 HPO 4 , 2.9 mM KCl, 12 mM NaHCO 3 , 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, 5.5 mM glucose, pH 7.3).
Other platelet assays
Aggregometry was performed with a PAP-8E aggregometer (Bio/Data Corporation, Alpha Laboratories (UK distributor), Hampshire, UK); details are given in the legend for Fig. 5 . Flow cytometry was performed with an Accuri C6 flow cytometer (BD, Oxford, UK) on washed platelets; details are given in the legend for Fig. 3 . Static platelet adhesion (Fig. 3 ) experiments were performed as described previously [4] to determine the effects of mFab-F and Hip8 (anti-aIIbb3) on adhesion of washed platelets to fibrinogen-substrate-coated or collagen-coated ELISA plates.
Confocal imaging
Washed platelets (3 9 10 7 mL À1 in HT/2 mM MgCl 2 )
were allowed to adhere on fibrinogen-substrate-coated MatTek dishes for 1 h at 37°C and formalin fixed as described previously [31] . Pre-and post-staining details are provided in the figure legends. Stained samples were imaged under an Olympus FV300 IX81 laser-scanning confocal microscope (Olympus, Essex, UK), with a 60x oil immersion objective).
Effect of anti-GPVI-dimer antibodies on platelets under flow
Flow adhesion experiments were performed with normal or GT blood and image acquisition was carried out as described [32] ; details are given in the figure legends. After 5 min, Z-stacks (DZ = 0.69-lm increments from the coverslip plane) were collected and analyzed by ImageJ1.35 (National Institutes of Health). The coverslip plane was defined as the Z-plane with the largest fluorescent platelet area and used to calculate the surface area coverage (SA; lm 2 ). Thrombus volume (lm 3 ) was calculated as the sum of the detected surface areas of all images in the Z-stack, multiplied by DZ. Mean thrombus height (MTH) was calculated as thrombus volume/field area.
Data analyses
Non-linear regression (one-site model) to obtain dissociation constants (K d ) and statistical analyses was performed with Prism version 7.2 (GraphPad Software, San Diego, CA, USA).
Results
Dimeric, but not monomeric, GPVI binds to immobilized Dfragment and D-dimer with high affinity
We measured GPVI-Fc 2 binding to immobilized fibrinogen derivatives and collagen III (col III) ( Fig. 1A ; mean AE SEM, 3 experiments, duplicate replicates). GPVIFc 2 showed high levels of binding to D-fragment and Ddimer, but did not bind E-fragment. There was very low but measurable binding to fibrinogen, pFibrin and mFibrin. GPVI-Fc 2 binding to D-fragment or D-dimer was specific and saturable, their K d values being higher but similar in magnitude to that for col III (Fig. 1E) . At all coating concentrations (10-200 lg mL À1 , Fig. 1C ), did not bind D-fragment, D-dimer or fibrinogen and exhibited feeble col III binding compared with GPVI-Fc 2 , as previously reported [4] (Fig. 1B) . 
Furthermore, mFab-F significantly reduces GPVI-Fc 2 binding to D-fragment (P < 0.01), D-dimer (P < 0.01) and collagen type III (P < 0.05), compared with a nonspecific human Fab (hFab; Jackson ImmunoResearch) control (Fig. 5B ). These results suggest that the binding site for GPVI lies in the D-domain, universally present in fibrinogen, D-dimer, mFibrin and pFibrin, for which only GPVI-dimer has good affinity.
Human Fc and DDR2-Fc 2 (recombinant Fc-fusion protein of discoidin domain-containing receptor 2, another collagen-binding protein [33] ) and human IgG did not bind to any of the fibrinogen substrates, whereas DDR2-Fc 2 bound to collagen as expected, confirming the specificity of our assay to the GPVI portion of GPVI-Fc 2 ( Fig. 1D ).
Collagenous substrates inhibit the binding of GPVI-dimer to D-fragment and D-dimer, suggesting proximity of binding sites
To determine if the binding site on GPVI-dimer for D-fragment and D-dimer is close to that for collagen, we incubated GPVI-Fc 2 (20 lg mL À1 ) with 0-20 lg mL À1 of col III (non-fibrous), Horm collagen (fibrous), CRP-XL and GPP10-XL and reacted it with immobilized D-fragment and D-dimer. The converse experiment, where immobilized collagenous substrates were reacted with GPVI-Fc 2 incubated with fibrinogen, fibrins or fibrinogen subdomains, was also performed (described in next section). Col III and Horm showed similar concentrationdependent abilities to inhibit binding of GPVI-Fc 2 to Dfragment, with complete inhibition at ≥ 0.5 lg mL
À1
( Fig. 2A-i ). CRP-XL was effective at lower concentrations, producing complete inhibition at ≥ 0.05 lg mL À1 .
Higher col III and Horm concentrations were needed to inhibit GPVI-Fc 2 binding to D-dimer, whereas the inhibition curve of CRP-XL was similar to that against D-fragment ( Fig. 2A -ii). As expected, GPP10-XL had little effect against GPVI-Fc 2 binding. Flow cytometry (Fig. 5C ) shows that the washed normal platelets bind to fibrinogen and D-dimer, at a low level, but thrombasthenic platelets that lack aIIbb3 exhibit no binding to either. This means that activation through aIIbb3 is required for expression of D-dimer and fibrinogen binding; in this case, the platelets may have become slightly activated during the washing procedures.
pFibrin (> 5 lg mL À1 ) was able to induce platelet aggregation ( Figure S2 ); mFab-F prolonged its lag-time but did not reduce maximum aggregation, whereas 45-lM Eptifibatide (anti-aIIbb3) abrogated it. This suggests that platelet aggregation through pFibrin in suspension doesn't require GPVI-dimer. Fibrinogen, D-fragment and D-dimer (5-20 lg mL
) did not induce platelet aggregation ( Fig. 5A-i) . However, D-dimer concentration-dependently inhibited Horm-induced aggregation of washed platelets (Fig. 5A-ii) . In platelets pre-incubated with 100 lg mL À1 Horm, lower D-dimer concentrations did not affect mFab-F inhibition of Horm-induced aggregation, but high D-dimer concentration relieves the inhibition, suggesting that D-dimer may bind at a Fig. 1 . Interaction of GPVI-Fc 2 and GPVI ex with immobilized fibrinogen derivatives. The following abbreviations were used in the graphs: Figure S1 and the corresponding polymerized (pFibrin) and monomeric fibrins (mFibrin) produced from thrombin +/À GPRP addition, respectively. Fluorescence values shown are the mean AE SEM, from five different experiments, with duplicate repeats in each. GPVI-Fc 2 (50 lg mL separate but nearby site, perhaps producing a conformational change that may reduce the affinity of mFab (Fig. 5A-iii) .
Therefore, fibrinogen derivatives in solution are not able to bind to platelet GPVI-dimer or GPVI-Fc 2 . Although D-dimer appears to bind to GPVI-dimer in suspension, it does not cause aggregation, and indeed inhibited it, an important physiological barrier to prevent platelets from spontaneous aggregation through GPVIdimer.
Platelet adhesion to fibrinogen substrates under static conditions and effect of inhibiting antibodies
Under static conditions, washed platelets adhere to fibrinogen, D-fragment, pFibrin, mFibrin and D-dimer ( Fig.   3 ), but not to E-fragment (data not shown in Fig. 3 ). mFab-F mildly but significantly inhibited platelet adhesion to D-fragment, mFibrin, pFibrin and col III, whereas hFab (human Fab) had no effect. Hip8 dramatically decreased platelet adhesion on fibrinogen, D-fragment, D-dimer, mFibrin and pFibrin. mFab-F + Hip8 further decreased platelet adhesion on D-fragment, Ddimer, mFibrin and pFibrin. Thus, static adhesion to fibrinogen substrates is mainly aIIbb3-dependent, with a small contribution by GPVI-dimer. In contrast, static ) and Hip8 (10 lg mL
À1
), was determined as previously described; in this assay, the adhered platelets are lysed and their content of alkaline phosphatase measured in an assay using the chromogenic substrate p-nitrophenyl phosphate, which is hydrolyzed by this enzyme to p-nitrophenol, which is detectable at 405-nm absorbance. Data shown are the mean AE SD of three separate experiments, each data point run in duplicate, using platelets from three different healthy control individuals. Data were analyzed by the paired t-test, with significances shown on the figure: control (human Fab) vs. mFab-F, Hip8 or mFab8 + Hip8 (*P < 0.05, **P < 0.01,***P < 0.001); mFab vs. Hip8 (**P < 0.01, ***P < 0.001); Hip8 vs. Hip8 + m-Fab-F (a*P < 0.05,**P < 0.01); ns = not significant. Platelets adhere to fibrinogen, pFibrin (polymerized fibrin made from Fib-3), mFibrin (monomeric fibrin made from Fib-3), D-fragment, D-dimer and collagen type III (col III), the positive control. Platelets do not adhere to E-fragment, so the following discussion of antibody effects only refers to the substrates supporting platelet adhesion. mFab-F mildly but significantly decreased platelet binding to D-fragment, m-fibrin, p-fibrin and collagen. Hip8 markedly decreases platelet adhesion to all fibrinogen substrates, but has no effect on platelet adhesion to collagen, which is mainly supported by integrin a2b1. Adding mFab-F and Hip8 together further diminishes platelet adhesion to all immobilized fibrinogen substrates, suggesting that integrin aIIbb3 plays the predominant role but GPVI-dimer makes a significant contribution. Src inhibitor Dasatinib (50 nM) for 10 min and then were allowed to adhere to fibrinogen, fibrinogen derivative or Horm collagen immobilized on MatTek glass dishes, followed by fixation and staining with fluorescently labelled antibody (as described in the Methods). (A) Images show platelets stained with Alexa-fluor 488-1G5 (green; pan GPVI) and Alexa-fluor 647-anti-P-selectin (red) to measure platelet activation. Images were obtained with a 60x oil immersion objective on an Olympus confocal microscope. As shown in (A) (left-most column of images), platelets spread well on fibrinogen, D-fragment, mFibrin and Horm collagen, with evident surface expression of P-selectin. Platelet aggregate formation was seen on pFibrin, whereas platelets spread but did not appear aggregated on mFibrin. Horm collagen supported aggregate formation, with the characteristic binding of GPVI along the Horm fibers [31] . In contrast, platelets did not spread well on D-dimer, with only some platelets showing P-selectin expression. Treatment with mFab-F (A, middle column of images) prevented platelet spreading on fibrinogen, D-fragment and Horm collagen, and decreased the extent of spreading, with evident filopodia observed, on mFibrin and pFibrin, whereas there was little change in the less-spread platelets on D-dimer. mFab-F prevented aggregate formation on both pFibrin and Horm collagen, consistent with inhibition of activation through GPVI. Dasatinib (A, right-most column of images) shows effects similar to those of mFab-F. (B) In these experiments, the immobilized pFibrin or mFibrin (data not shown) was stained with anti-fibrin/Alexa-fluor 547-anti-mouse IgG (blue) after the surface was blocked with 1% bovine serum albumin; the dishes were then thoroughly washed and used for the platelet adhesion experiments, which were performed as shown in (A). pFibrin (blue) is clearly evident, whereas there was no staining of the immobilized mFibrin (data not shown). P-selectin (red) expression and aggregate formation is evident on the surface of the adhered platelets. [Color figure can be viewed at wileyonlinelibrary.com] adhesion on collagen mainly depends on a2b1, with a lesser contribution by GPVI-dimers, under the present noncation-depleted conditions [4] .
Platelet spreading on immobilized fibrinogen substrates requires GPVI-dimer
Confocal images (Fig. 4A ) of platelets labeled for pan-GPVI (Alexa-fluor 488-1G5, green) and P-selectin (Alexa-fluor 647-anti-CD 62p, red) indicate that platelets spread well, with P-selectin expression, on fibrinogen, D-fragment, mFibrin and pFibrin, which shows clear aggregate formation. Little spreading occurred on D-dimer. mFab-F and Dasatinib (Src-kinase inhibitor) cause similar inhibition of platelet spreading on fibrinogen and D-fragment, and although platelets still spread on pFibrin, aggregate formation is obviously reduced. As expected, platelets bind through GPVI on Horm fibers, with surface P-selectin expression, as reported before [31] . Figure 4 (B) shows a representative image of immobilized pFibrin fibers, pre-stained as described in the Methods, before platelets were added, with adhered (PPACK) and topped up at 1 : 1000 ratio every hour. Platelets in whole blood were fluorescently labelled with 1:4500 DiOC6 (3,3 0 -dihexyloxacarbocyanine iodide). After 1-min perfusion of flow buffer (136 mM NaCl, 2.7 mM KCl, 5 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, 10 mM glucose, 2 mM MgCl 2 , 2 mM CaCl 2 , pH 7.4), whole blood was perfused over the coverslips at a shear rate of 350 s À1 . Z-stack images were used to calculate surface coverage (SA) of adhered platelets and mean thrombus height (MTH) in panels B-E. (A) Fluorescently labelled whole blood was left untreated (control) or treated with one of the following: human Fab (hFab, 100 lg mL
À1
), mFab-F (GPVI-dimer specific, inhibitory; 100 lg mL À1 ), Eptifibatide (aIIbb3 inhibitor, 45 lM; Tocris Bioscience, UK), Gi9 (anti-a2b1, inhibitory; GeneTex, USA). The images in Panel A are representative of six flow experiments performed with blood from different donors. Statistical significance between control and antibody inhibition (B + C) or human Fab and mFab-F inhibition (D + E) was calculated using paired t-tests (*P < 0.05, **P < 0.01 ***P < 0.001). (B + C) Inhibition of aIIbb3 abrogated SA and MTH to all surfaces. mFab-F reduced platelet adhesion (SA) to all five fibrinogen derivatives (D-fragment, **P < 0.01; all others, *P < 0.05) and col III (*P < 0.05). mFab-F also significantly suppressed MTH on D-fragment, mFibrin and col type III (**P < 0.01) and reduced it on D-dimer, fibrinogen and pFibrin compared with the control. This suggests that GPVI-dimer is able to facilitate platelet adhesion and thrombus growth on fibrinogen derivatives, through the D-domain. (C + D) The inhibition of GPVI-dimer with mFab-F compared with the effect of human Fab and anti-a2b1 Gi9 under the same conditions. a2b1 had little to no effect on adhesion to fibrinogen derivatives, and as expected caused some reduction of aggregate formation (MTH) on collagen. mFab-F significantly reduced SA and MTH compared with human Fab on all tested substrates, except SA on D-fragment and D-dimer, which nevertheless tended towards significance (P = 0.07 and P = 0.08, respectively). [Color figure can be viewed at wileyonlinelibrary.com] platelets showing pan-GPVI and surface P-selectin expression.
Both GPVI-dimer and integrin aIIbb3 contribute to platelet adhesion and thrombus formation on fibrinogen derivatives under flow conditions Human blood from a healthy donor was perfused over immobilized fibrinogen derivatives or col III (control) at 350 s À1 (Fig. 6 ) and 1000-s À1 ( Figure S3 ). Thrombus formation is apparent on all control images (left column, Fig. 6A ). Addition of mFab-F (middle column of images, Fig. 6A ) decreases both platelet adhesion (SA) (Fig. 6B ) and mean thrombus height (MTH) (Fig. 6C ) on all tested surfaces. Eptifibatide abrogated platelet adhesion on all four fibrinogen derivatives (right column, Fig. 6A ). Inhibition of a2b1 by mAb Gi9 (10 lg mL
) only mildly inhibited adhesion on collagen, but not the fibrinogen substrates. Compared with hFab (100 lg mL In these experiments, the ELISA wells were coated by adding a 100-lg mL À1 solution of each substrate. The GT platelets did not adhere to fibrinogen or D-fragment, but retained the ability to adhere to pFibrin and D-dimer, although this was markedly reduced. mFab-F markedly reduced the adhesion on pFibrin, suggesting that GPVI-dimer may be involved in this interaction. (C) Confocal images of normal platelet and GT platelets adhered to immobilized pFibrin. Both normal and GT platelets were prelabelled with Alexa fluor 488-conjugated 204-11 Fab and allowed to adhere on pFibrin-coated MatTek dishes, for 30 min at 37°C. The platelets were then fixed and stained with Alexa fluor 647-conjugated antibody specific for integrin aIIbb3 (normal platelets) or GPIb (GT platelets), as described in the text, before imaging. The GT platelets retain the ability to adhere to pFibrin, although they do not spread; close inspection of the transmitted light images shows that the GT platelets adhere on or close to the fibers of pFibrin. [Color figure can be viewed at wileyonlinelibrary.com] on all fibrinogen derivatives ( Fig. 6D and E) . All differences were statistically significant apart from mean SA on D-fragment and D-dimer, which was close to reaching significance (P = 0.07 and P = 0.08, respectively). This confirms that GPVI-dimer contributes to platelet adhesion and thrombus formation on immobilized fibrinogen and fibrin surfaces, although the effect of aIIbb3 is greater.
Assessing the role of GPVI-dimer in platelets from a patient with Glanzmann's thrombasthenia (GT)
Because platelets contain far fewer GPVI-dimers than integrin aIIbb3, which may mask the subtler effects of GPVI-dimer, we examined static adhesion and flow adhesion using blood from a GT patient, whose platelets were confirmed to have no aIIbb3 but a normal GPVI level (Fig. 7A) . Static adhesion of GT platelets: Washed GT platelets showed essentially no adhesion on fibrinogen or D-fragment, but retained a low level of adhesion on pFibrin and D-dimer (Fig. 7B ). mFab-F (100 lg mL
) further diminished the adhesion to pFibrin, suggesting that this low level of interaction involved GPVI-dimer.
Confocal imaging showed that some GT platelets prelabelled with Alexa-fluor 488-conjugated 204-11-Fab (green) and post-labelled with Alexa-fluor 647-conjugated anti-GPIb (red) (Fig. 7C ) adhered to pFibrin fibers (Fig. 7C, transmitted light image) , but did not spread/aggregate like the normal platelets (post-labelled with Alexa-fluor 647-conjugated anti-aIIbb3). Under flow conditions, adhesion of GT platelets to D-fragment, D-dimer, fibrinogen and pFibrin was dramatically reduced, but platelet adhesion was still evident (Fig. 8A) . Quantitation of SA (Fig. 8B) showed that GT platelets retain some ability to adhere to fibrinogen, pFibrin, D-fragment and D-dimer. Their SA on D-fragment and D-dimer was reduced by mFab-F, suggesting GPVIdimer involvement in this adhesion. MTH for the GT platelets (Fig. 8C) was very low, indicating little platelet activation had occurred. This suggests that the absence of aIIbb3 does not abolish the interaction between GPVI and fibrinogen substrates, although it appears that its absence impairs the ability of platelets to activate on fibrinogen and fibrin.
to adhesion but also to spreading on fibrinogen, D-fragment, mFibrin, and pFibrin, and aggregate formation on pFibrin (Fig. 4) .
Platelet adhesion to fibrinogen substrates under flow is more complex than measuring direct binding using ELISA, because it involves a dominant role for aIIbb3 at lower (350 s
) and higher (1000 s À1 ) shear, as demonstrated by the abrogation of thrombus formation in the presence of Eptifibatide (Fig. 6, Figure S3 ). GPVI-dimer, however, appears to play its most significant role at low shear, because mFab-F significantly decreases SA on all tested substrates and MTH is significantly reduced on D-fragment, mFibrin and collagen (Fig. 6 , Table S1 ). At 1000 s
, GPVI inhibition appears to produce more variable results, which suggests that GPVI-dimer is less able to recognize immobilized D-domain at higher shear. This indicates that aIIbb3 does play a significant role in platelet interactions with fibrinogen and fibrin in both static (Fig. 3) and shear ( Fig. 6 ) conditions, whereas GPVIdimer has a secondary but requisite role for inducing platelet adhesion and thrombus formation.
This could be through convergent tyrosine kinase signaling downstream from GPVI and aIIbb3. For example, the crosslinking of GPVI induces Src-dependent tyrosine phosphorylation of FcRc [2] and, similarly, signaling mediated by aIIbb3 also includes tyrosine kinases such as Syk and Src [38, 39] , with specific blockade reducing the tyrosine phosphorylation of signaling proteins downstream from Syk in both the GPVI and aIIbb3 signaling pathways [40] . Dasatinib and mFab-F each exert a similar inhibitory effect on platelet adhesion, indicating platelet-adhesion-induced signaling through GPVI-dimer is an important step in platelet spreading and activation on fibrinogen and fibrin (Fig. 4) . This is consistent with Onselaer et al., who show that fibrin is unable to activate GPVI-deficient human platelets, which is further evidence of shared signaling pathways between GPVI and aIIbb3 [26] .
Under static conditions, aIIbb3-deficient GT platelets can adhere to pFibrin, but are not activated (Fig. 7) . Under flow, the GT platelets show drastically reduced adhesion to D-fragment, D-dimer, fibrinogen and pFibrin, but residual adherent but non-spread platelets remain (Fig. 8) . mFab-F reduces GT platelet adhesion on all substrates tested, suggesting that GT platelets can bind independently through GPVI-dimer, even without functional aIIbb3, but these adhered GT platelets appear neither spread nor activated, suggesting that signaling may not occur without the assistance of aIIbb3. This means that platelet surface GPVI-dimers may support a weak interaction with immobilized fibrinogen or fibrin, but it is not sufficient to initiate platelet activation. It is more likely that aIIbb3 and GPVI-dimer have collaborative roles in platelet activation on fibrinogen and fibrin, especially as platelets treated with both mFab-F and Hip8 show a further decrease in adhesion compared with Hip8 alone (Fig. 3) .
GPVI antagonism could provide highly specific pharmacological drugs that prevent thrombus formation in acute coronary syndrome [41] and ischemic stroke [42] . This study is the first to describe an interaction between GPVI-dimer and fibrinogen and fibrin. GPVI-dimer binds to the D-domain and is involved in signaling, leading to platelet spreading and activation on fibrinogen substrates, in conjunction with aIIbb3 and independent of collagen exposure. GPVI-dimer clearly plays a key part in both initiation and propagation of thrombosis at sites of atherosclerotic plaque rupture through collagen and fibrin. However, our findings also intimate a role for GPVI-dimer in conditions where blood clots form without collagen exposure, including atrial fibrillation and deep vein thrombosis, making it an even more tantalizing pharmacological target. 
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